IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aurobindo and Celon Laboratories form generics JV to cater US and Europe

9:53 AM MST | December 10, 2013 | Natasha Alperowicz

Celon Laboratories (Hyderabad, India) said on Monday that it has entered into an agreement with Aurobindo Pharma (Hyderabad) to form a joint venture to develop, manufacture, and sell hormonal and oncology generic formulations for the US and European markets. A special-purpose vehicle company, Eugia Pharma Specialties, will be formed and in which Aurobindo will hold 60% and Celon 40%. The companies will invest a combined 1.8–2.0 billion Indian rupees ($29.5–32.8 million) in the jv over the next two to three years. Aurobindo, in August, agreed to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa